Orexigen corrects weight-loss Phase III data, shares fall
This article was originally published in Scrip
Orexigen Therapeutics has said that fewer patients met the endpoints of one of the Phase III studies for its weight-loss combination candidate Contrave (naltrexone SR plus bupropion SR) than it had originally stated.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.